Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk
JAMA Cardiology
JUNE 25, 2024
This genetic association study evaluates the association of genetic variants with atrial fibrillation, cardiomyopathy, and heart failure.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
JAMA Cardiology
JUNE 25, 2024
This genetic association study evaluates the association of genetic variants with atrial fibrillation, cardiomyopathy, and heart failure.
Frontiers in Cardiovascular Medicine
JANUARY 16, 2024
Introduction Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n = 27) had persistent atrial fibrillation.
HeartRhythm
MAY 22, 2024
Percutaneous left atrial appendage closure (LAAC) is an effective alternative strategy for stroke prevention in atrial fibrillation (AF) patients at high risk for bleeding with anticoagulation (AC). Efficacy of this strategy in hypertrophic cardiomyopathy (HCM) remains uncertain.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation(AF) is associated with increased risk of embolic stroke and heart failure hospitalizations in patients with hypertrophic cardiomyopathy(HCM).
HeartRhythm
APRIL 30, 2024
Catheter ablation is recommended in patients with suspected atrial fibrillation-mediated cardiomyopathy (AMC) for the recovery of cardiac function.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) is highly prevalent in patients with hypertrophic cardiomyopathy (HCM) as well as other cardiomyopathy (CM) phenotypes.
HeartRhythm
APRIL 12, 2024
Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM).1 1 In late-stage clinical trials, atrial fibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten.1,2
Dr. S. Venkatesan MD
APRIL 28, 2024
When atrial fibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.
HeartRhythm
SEPTEMBER 19, 2023
In patients with hypertrophic cardiomyopathy (HCM), atrial fibrillation (AF) poses significant clinical challenges because of its adverse impact on hemodynamics. AF, especially when accompanied by rapid ventricular responses, compromises atrial contraction and in turn increases diastolic filling of the left ventricle.
HeartRhythm
AUGUST 23, 2023
Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and can be challenging to manage. Atrioventricular nodal (AVN) ablation may be an effective management strategy for AF in these patients.
HeartRhythm
APRIL 30, 2024
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF).
Journal of Cardiovascular Electrophysiology
JANUARY 30, 2024
Abstract Introduction In hypertrophic cardiomyopathy (HCM), atrial fibrillation (AF) has historically been regarded to have a deleterious impact on clinical course, strongly associated with progressive heart failure (HF) symptoms. Results Among the 218 patients, 50 (23%) had a history of AF and comprise the primary study cohort.
Circulation
NOVEMBER 11, 2024
She was found to have atrial fibrillation and flutter with RVR. Cardiomyopathy and arrhythmia have been described in a small number of cases. Beta blockers and angiotensin receptor antagonists are used in slowing aortic dilatation; cardiomyopathy and arrhythmias should be treated according to established guidelines.
Circulation
NOVEMBER 11, 2024
While studies have linked this genetic mutation to severe cardiac hypertrophy, a connection to persistent atrial fibrillation (AF) is unestablished. While no definitive link exists between BHDS and cardiomyopathy, we aim to understand possible connections between this rare condition and its systemic cardiovascular impacts.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) has been known as a main cause of embolic stroke. Atrial mechanical remodeling presenting cardiomyopathy could lead to not only occur AF but also increase risk of thromboembolism.
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF), a common cardiac arrhythmia, often results in significant atrial remodeling, including atrial cardiomyopathy and dilatation. Notably, aFMR is linked to a higher recurrence rate of AF after catheter ablation.
Heart BMJ
JUNE 25, 2024
Hypertrophic cardiomyopathy (HCM) stands as one of the most common inheritable myocardial disease and is often marked by its association with sudden cardiac death (SCD) in the young. 1 2 Traditionally, risk assessment in HCM has focused mainly on estimating the likelihood of SCD.
American College of Cardiology
OCTOBER 23, 2024
What is the impact of atrial fibrillation (AF) catheter ablation in patients with hypertrophic cardiomyopathy (HCM) on reduction in AF burden and symptoms?
HeartRhythm
JANUARY 18, 2024
Atrial fibrillation (AF) in patients with hypertrophic obstructive cardiomyopathy (HOCM) may be caused by a primary atrial myopathy. Whether HOCM-related atrial myopathy affects mainly electrophysiological properties of the left atrium (LA) or also the right atrium (RA) has never been investigated.
Dr. Smith's ECG Blog
APRIL 2, 2024
So it must be atrial fibrillation. Answer : it is irregularly irregular and the initial part of the QRS is fast, so this is atrial fibrillation with Left Bundle Branch Block (LBBB). Patient has an ICD, which is primarily placed in patients with cardiomyopathy. What do you think? mm; the S-wave is 18 mm.
The American Journal of Cardiology
SEPTEMBER 26, 2024
Publication date: Available online 26 September 2024 Source: The American Journal of Cardiology Author(s): Eduard Ródenas-Alesina, Jordi Lozano-Torres, Pablo Eduardo Tobías-Castillo, Clara Badia-Molins, Maria Calvo-Barceló, Rosa Vila-Olives, Guillem Casas-Masnou, Aleix Olivella San Emeterio, Toni Soriano-Colomé, Rubén Fernández-Galera, Ana B Méndez-Fernández, (..)
Circulation
NOVEMBER 11, 2024
Background:Obstructive sleep apnoea (OSA) is highly prevalent in patients with obstructive hypertrophic cardiomyopathy (oHCM), and the severity of OSA appears to worsen following septal myoectomy. vs. 27.77 ± 3.26, p<0.001), a higher proportion of atrial fibrillation, hypertension, and history of smoking.
American College of Cardiology
NOVEMBER 21, 2024
New science presented at AHA 2024 and simultaneously published in JACC: Advances provide insights on emerging topics such as the use of artificial intelligence (AI)-enabled left atrial (LA) volumetry in coronary artery calcium (CAC) scans to predict atrial fibrillation (AFib); the role of treating hospitals in facilitating cardiac rehabilitation (CR); (..)
HeartRhythm
DECEMBER 26, 2023
Atrial cardiomyopathy is known as an underlying pathophysiological factor in the majority of AF patients. Left atrial low-voltage areas (LVAs) are reported to coincide with fibrosis, and to likely represent atrial cardiomyopathy.
Circulation: Arrhythmia and Electrophysiology
NOVEMBER 29, 2023
Atrial cardiomyopathy is a condition that causes electrical and contractile dysfunction of the atria, often along with structural and functional changes. Atrial enlargement and atrial fibrillation are common complications of ASCM and are often the predominant clinical features.
HeartRhythm
JANUARY 23, 2024
The EHRA/HRS/APHRS/SOLAECE Expert Consensus on Atrial Cardiomyopathies published in 2017 defined atrial cardiomyopathy as “any complex of structural, architectural, contractile, or electrophysiological changes affecting the atria.”1
Dr. Smith's ECG Blog
MARCH 28, 2024
male with pertinent past medical history including Atrial fibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Of course, this is NOT atrial fib, but rather PSVT, and so adenosine should work.
DAIC
JUNE 4, 2024
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment 8.
The American Journal of Cardiology
APRIL 17, 2024
Publication date: Available online 16 April 2024 Source: The American Journal of Cardiology Author(s): Muhammad Usman Almani, Khawaja Muhammad Talha, Laibah Arhsad Khan, Ishaque Hameed, Zain Ul Abideen Asad, Marat Fudim, Richard Krasuski, Muhammad Shahzeb Khan
American College of Cardiology
JUNE 5, 2024
In this week’s View, Dr. Eagle looks at anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting. He then examines a meta-analysis of invasive vs. conservative management of non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting.
HeartRhythm
AUGUST 31, 2024
Artificial intelligence (AI)-enabled electrocardiography (ECG) scores can predict atrial fibrillation (AF) and grade atrial cardiomyopathy. Advanced stages present with left atrial fibrosis that can be identified by low-voltage areas (LVAs).
American College of Cardiology
MAY 6, 2024
Although atrial fibrillation/atrial flutter (AFib/AFL) are common manifestations of transthyretin amyloid cardiomyopathy (ATTR-CM), a post hoc analysis of the ATTR-ACT study, published April 30 in JACC: CardioOncology, found they do not predict all-cause mortality.
Journal of the American Heart Association
FEBRUARY 23, 2024
BackgroundRecent studies have indicated high rates of future major adverse cardiovascular events in patients with Takotsubo cardiomyopathy (TC), but there is no well‐established tool for risk stratification. Journal of the American Heart Association, Ahead of Print.
All About Cardiovascular System and Disorders
APRIL 30, 2024
Hypertrophic cardiomyopathy is a genetic disorder with a guarded prognosis which occurs in about 1:500 individuals. The most common symptom of hypertrophic cardiomyopathy is dyspnoea which occurs in 90% of cases and is due to elevated left ventricular diastolic pressures as a consequence of the diastolic dysfunction.
Circulation: Arrhythmia and Electrophysiology
OCTOBER 25, 2023
BACKGROUND:The cause of hypertrophic cardiomyopathy (HCM) in the young is highly varied. Six (21%) patients had clinical atrial fibrillation (1 with shortest preexcited RR interval <250 ms). Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012191, November 1, 2023.
ECG Cases
SEPTEMBER 12, 2023
The post ECG Cases 45 ECG in Weakness and Neurological Symptoms appeared first on Emergency Medicine Cases.
Journal of Cardiovascular Electrophysiology
MARCH 3, 2024
Complete left bundle branch block (CLBBB)-like QRS morphology of right ventricular pacing at pacemaker implantation satisfying the American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society criteria of CLBBB was associated with development of pacing induced cardiomyopathy.
European Journal of Heart Failure
DECEMBER 22, 2023
Abstract Background and aims In the EXPLORER-HCM trial, mavacamten reduced left ventricular outflow tract obstruction (LVOTO) and improved functional capacity of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients. kg/m 2 p<0.0001) and a more frequent history of atrial fibrillation (21.5% vs 9.8%, p=0.027).
HeartRhythm
AUGUST 13, 2024
Cardiac amyloidosis (CA) involves the abnormal accumulation of misfolded proteins in the heart muscle, leading to restrictive cardiomyopathy.1 Atrial arrhythmias (AA), particularly atrial fibrillation (AF), are prevalent in CA and may impact long-term cardiovascular outcomes, prompting an investigation into early rhythm management strategies.2
HeartRhythm
NOVEMBER 30, 2023
The advent of transseptal puncture has enabled the study of atrial fibrillation mechanisms, while epicardial access has enabled exploration of the epicardium in ventricular arrhythmias (ventricular tachycardia/ventricular fibrillation [VF]).1,2
HeartRhythm
APRIL 30, 2024
AF is the most common sustained arrhythmia in HCM. The ability of predicting AF in the HCM population is limited.
HeartRhythm
FEBRUARY 12, 2024
Atrial cardiomyopathy represents structural and electrophysiologic abnormalities associated with atrial fibrillation (AF). Voltage data is readily acquired in an ablation procedure but comparing voltage between subjects is complicated by variation in atrial size and orientation.
EMS 12-Lead
AUGUST 25, 2024
Examples of cardio embolic stroke etiology include: 1. Atrial Fibrillation 2. Cardiomyopathy with mural thrombus 3. Patent Foramen Ovale 4. Severe calcific Aortic (valve) Stenosis 5. Mechanical prosthetic valve Severe carotid artery stenosis is also implicated in embolic stroke. Here is the admission ECG.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
We aimed to investigate the safety of intravenous tissue plasminogen activator (IV tPA) and mechanical thrombectomy (MT) for acute ischemic stroke (AIS), and compare the functional outcome in cardiomyopathy patients with and without HF. Additionally, CM‐HF patients had higher rates of medical comorbidities such as atrial fibrillation (43.6%
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content